RWM
BDTX icon

Ritholtz Wealth Management’s Black Diamond Therapeutics BDTX Stock Holding History

Ritholtz Wealth Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$352K Sell
165,333
-62,537
-27% -$149K 0.01% 915
2025
Q4 		$554K Buy
227,870
+126,391
+125% +$448K 0.01% 688
2025
Q3 		$385K Buy
+101,479
New +$297K 0.01% 759

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ritholtz Wealth Management's BDTX Position: Q1 2026 in Review

Ritholtz Wealth Management reduced its Black Diamond Therapeutics (BDTX) stake by 27% in Q1 2026, selling an estimated $149K and leaving 165,333 shares worth $352K. The position accounts for 0.01% of the portfolio, ranked #915.

Ritholtz Wealth Management first reported a position in BDTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $554K in Q4 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Ritholtz Wealth Management held 165,333 shares of Black Diamond Therapeutics worth $352K as of Q1 2026.
  • Ritholtz Wealth Management sold 62,537 Black Diamond Therapeutics shares in Q1 2026, an estimated $149K.
  • Black Diamond Therapeutics made up 0.01% of Ritholtz Wealth Management's portfolio in Q1 2026, its #915 holding.
  • Ritholtz Wealth Management first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Ritholtz Wealth Management's Black Diamond Therapeutics position peaked at $554K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Ritholtz Wealth Management's 13F filing for Q1 2026, filed 20 Apr 2026.